drugset / Trial / NCT06888492
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).
Timeline
- Start
- 2025-03-28
- Primary completion
- 2026-04-25
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EXG202 | Gene therapy (AAV / viral vector) | — | Intravitreal |